novartis glp-1 receptor agonist weight management diabetes treatments Agonists as for Type 2 GLP-1 Receptor Agonists as Treatments
Description
The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.
no major safety concerns were observed
Ph 2 datathat showed weight loss of between 9.4% and 14.7% after 36 weeks on the drug compared to 2.3% for the placebo group and is currently in Ph 3
Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of ...
Read Important Safety and Prescribing Information, including Boxed Warning.
